((RAIN)) Rainmakers-Island

[The Rainmaker]

NMUS CEO: Interview: I will say, I can safely say that with $20 million financing that we will aggressively look at uplisting either to the Nasdaq or the NYSE. We think it’s very important to ultimately uplist so that we can get analysts’ coverage.

It is our plan, to use Marinol [another cannabinoid-based drug for this indication] as a reference drug in order to file a 505(b)(2) filing with the FDA. Our estimated timeline on that is towards the end of this year in the third or fourth quarter to go to the FDA.

We are currently in the process of developing a clinical-grade formulation or an eye drop for this indication, and then from there, we will submit a research dossier to the FDA in a pre-IND meeting so that we could begin human trials. We project that we could be in our first human studies in glaucoma early next year.